Table 1. Laboratory hormone and tumor markers of the patient.
| Hormone or tumor marker | Result | Normal range | Unit | |
|---|---|---|---|---|
| Preoperative | Postoperativea) | |||
| FSH | 9.3 | 23.8 | 0.8–15.7 | mIU/mL |
| LH | 5.2 | 16.8 | 1–20 | mIU/mL |
| Prolactin | 8.2 | - | 3.8–31.4 | ng/mL |
| Cortisol | 10.4 | - | 6.0–25.0 | mcg/dL |
| Growth hormone | <0.05 | - | 0.1–8.0 | ng/mL |
| E2 | 48.5 | 12.4 | 15–350 | pg/mL |
| Testosterone (total) | 13.52 | <0.09 | 0.09–1.6 | nmol/L |
| Sex hormone binding globulin | 30.4 | 34.3 | 6–152 | nmol/L |
| Free testosterone index | 44.5 | 1.3 | 0.4–19.6 | - |
| IGF-1 (somatomedin-C) | 119 | - | 55–248 | ng/mL |
| ACTH | 4.8 | - | 3.5–13.2 | pmol/L |
| C-peptide-anteprandial | 4.52 | - | 0.6–2.3 | ng/mL |
| C-peptide-postprandial | 10.46 | - | 0.6–2.3 | ng/mL |
| Insulin-anteprandial | 29.9 | - | 1.0–10.7 | mcIU/mL |
| Insulin-postprandial | 122.4 | - | 1.0–10.7 | mcIU/mL |
| HbA1c (NGSP) | 6.4 | 6.0 | 4.8–6.3 | % |
| HbA1c (IFCC) | 46 | 42 | 29–45 | mmol/mol |
| eAG | 137 | 126 | 91–134 | mg/dL |
| DHEA-S | 71.8 | 76.5 | 35.0–430.0 | mcg/dL |
| 17-hydroxyprogesterone | 2.05 | 0.93 | 0.11–5.00 | ng/mL |
| 5a-dihydrotestosterone | 0.54 | 0.07 | 0.05–0.30 | ng/mL |
| CA 19-9 | 8.9 | - | 0.8–24.0 | U/mL |
| CA 125 | 14.7 | - | 0.6–35.0 | U/mL |
| alpha-fetoprotein | 3.1 | - | 1.1–5.0 | ng/mL |
FSH, follicle-stimulating hormone; LH, luteinizing hormone; E2, estradiol; IGF-1, insulin-like growth factor 1; ACTH, adrenocorticotropic hormone; NGSP, national glycohemoglobin standardization program; IFCC, International Federation of Clinical Chemistry; eAG, estimated average glucose; DHEA-S, dehydroepiandrosterone sulfate; CA, cancer antigen.
a)For values that were initially abnormal, follow-up was performed 3 weeks postoperatively.